The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1028
June 5, 1998
View Complete Issue         Table of Contents 2019 
Clopidogrel for Reduction of Atherosclerotic Events
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Clopidogrel for Reduction of Atherosclerotic Events
June 5, 1998 (Issue: 1028)
Clopidogrel bisulfate (Plavix - Bristol-Myers Squibb/Sanofi), a new thienopyridine antiplatelet agent similar to ticlopidine (Ticlid - Medical Letter, 34:65, 1992), has been approved by the US Food and Drug Administration (FDA) for secondary...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Clopidogrel for Reduction of Atherosclerotic Events
Article code: 1028a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.